Trials / Completed

CompletedNCT00192452

Study of MEDI-507 Administered by Intravenous Infusion to Adults With Plaque Psoriasis

A Phase II Randomized, Double-Blind, Placebo-Controlled Study of MEDI-507, a Humanized Monoclonal Antibody That Binds to the CD2 Receptor, Administered by Intravenous Infusion to Adults With Plaque Psoriasis

Status: Completed
Phase: Phase 2
Study type: Interventional
Enrollment: 120 (planned)

Sponsor: MedImmune LLC · Industry
Sex: All
Age: 18 Years – 64 Years
Healthy volunteers: Not accepted

Summary

\- The primary objective of this study is to compare disease activity, as measured by PASI score, of two MEDI-507 dose levels (0.012 and 0.04 mg/kg) versus placebo administered by intravenous infusion every 2 weeks for a total of 8 infusions.

Conditions

Psoriasis

Interventions

Type	Name	Description
DRUG	MEDI-507

Timeline

Start date: 2001-03-01
Completion: 2001-12-01
First posted: 2005-09-19
Last updated: 2006-10-25

Locations

3 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00192452. Inclusion in this directory is not an endorsement.